Physician profile
Michael Moffa
NPI 1225147002
$1,797.01
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $93.91 · 2021: $138 · 2022: $495 · 2023: $153 · 2024: $375 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $425.43 | 2019-2024 | Ovitex 2s |
| Medtronic, INC. | $206.95 | 2022-2025 | Interstim |
| Braintree Laboratories, INC. | $192.81 | 2019-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $173.07 | 2019-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $163.43 | 2019-2025 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.42 | 2019-2024 | Xifaxan, Plenvu |
| Aroa Biosurgery Incorporated | $142.56 | 2022 | |
| Abbvie INC. | $117.37 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $52.26 | 2025 | |
| Ethicon US, LLC | $39.53 | 2025 | Evarrest |
| Acera Surgical, INC. | $34.84 | 2025 | Restrata Wound Matrix |
| Janssen Biotech, INC. | $34.07 | 2020-2022 | |
| Celltrion USA INC. | $23.65 | 2024 | Zymfentra |
| Convatec INC. | $16.28 | 2023 | |
| Shire North American Group INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.